Skip to content
Synopulse
  • News
  • Editor’s Feature
  • The Signal
  • NeuroPulse
  • Industry Trends
    • Market Access
    • Deals
    • Technologies
      • Cell & Gene Tx
      • Antibody
      • AI
      • MedTech
    • Legal, Antitrust & IP
    • Speciality
      • Neurology
      • Orthopaedics
      • Oncology
      • Cardiometabolic
      • Pediatrics
  • Regulatory
    • FDA Updates
    • EMA Updates
    • Global Compliance
  • The ShowFloor

NICE Annual Report

NICE Slashes Medicines Evaluation Times by 30%

July 17, 2026 by Athithi
NICE Slashes Medicines Evaluation Times by 30%

NICE recommended 66 new treatments last year and rejected seven but 25 evaluations were terminated before anyone ruled on them.

Categories Market Access Tags NICE, NICE Annual Report
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24 2025

Synopulse Weekly Pulse – November 24, 2025

Read Now
  • AI
  • Antibody
  • Cardiometabolic
  • Cell & Gene Tx
  • DealFlow
  • Deals
  • Dealstreet
  • Device Approvals
  • Editor’s Feature
  • EMA Updates
  • FDA Updates
  • Global Compliance
  • HTA
  • Industry Trends
  • Legal, Antitrust & IP
  • Litigation, Law & Policy
  • Market Access
  • Market Pulse
  • MedTech
  • Monthly Insight's
  • Neurology
  • NeuroPulse
  • News
  • Oncology
  • Orthopaedics
  • Pediatrics
  • Pricing and Reimbursement
  • Regulatory
  • Reports
  • Special Reports
  • The ShowFloor
  • The Signal
  • Weekly Pulse
  • July 2026
  • June 2026
  • May 2026
  • March 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress